Merus NV
NASDAQ:MRUS
Merus NV
NASDAQ:MRUS
Price:
45.02 USD
-0.42%
Market Closed
Updated:
May 17, 2024
Merus NV
Income from Continuing Operations
|
Merus NV
Income from Continuing Operations Peer Comparison
Comparables:
PHARM
PRQR
QURE
ARGX
N
NAMS
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Merus NV
NASDAQ:MRUS
|
Income from Continuing Operations
-$154.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Income from Continuing Operations
-$10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Income from Continuing Operations
-€26.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Income from Continuing Operations
-$308.5m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-23%
|
|
|
argenx SE
XBRU:ARGX
|
Income from Continuing Operations
-$295.1m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Income from Continuing Operations
-€78.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Merus NV's Income from Continuing Operations?
Income from Continuing Operations
-154.9m
USD
-154.9m
USD
Based on the financial report for Dec 31, 2023, Merus NV's Income from Continuing Operations amounts to -154.9m USD.
What is Merus NV's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-40%
-40%
Over the last year, the Income from Continuing Operations growth was -18%. The average annual Income from Continuing Operations growth rates for Merus NV have been -22% over the past three years , -40% over the past five years .
You don't have any saved screeners yet
